Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as...
3 insider purchases on record · latest filing 2025-01-28.
Insiders have also filed 6 sale transactions at IMNN.